175 related articles for article (PubMed ID: 8791779)
21. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
Ann Rheum Dis; 1999 Mar; 58(3):182-5. PubMed ID: 10364917
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
[TBL] [Abstract][Full Text] [Related]
23. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
Lou YQ; Kuang TY
Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
[TBL] [Abstract][Full Text] [Related]
24. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
De Morais SM; Wilkinson GR; Blaisdell J; Meyer UA; Nakamura K; Goldstein JA
Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
[TBL] [Abstract][Full Text] [Related]
26. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
Takakubo F; Kuwano A; Kondo I
Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
[TBL] [Abstract][Full Text] [Related]
27. Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction.
Griese EU; Läpple F; Eichelbaum M
Pharmacogenetics; 1999 Jun; 9(3):389-91. PubMed ID: 10471071
[No Abstract] [Full Text] [Related]
28. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.
Zhou HH
Clin Chim Acta; 2001 Nov; 313(1-2):203-8. PubMed ID: 11694260
[TBL] [Abstract][Full Text] [Related]
29. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A
Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219
[TBL] [Abstract][Full Text] [Related]
30. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase.
Hersberger M; Marti-Jaun J; Rentsch K; Hänseler E
Clin Chem; 2001 Apr; 47(4):772-4. PubMed ID: 11274039
[No Abstract] [Full Text] [Related]
31. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA
Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260
[TBL] [Abstract][Full Text] [Related]
32. Identification of the highly polymorphic S-mephenytoin hydroxylase in humans.
Soucek P; Guo Z; Sandhu P; Martin MV; Cosme J; Beaune PH; Guengerich FP
Arch Toxicol Suppl; 1996; 18():437. PubMed ID: 8678819
[No Abstract] [Full Text] [Related]
33. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
[TBL] [Abstract][Full Text] [Related]
34. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
Hall SD; Guengerich FP; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1987 Jan; 240(1):216-22. PubMed ID: 2879902
[TBL] [Abstract][Full Text] [Related]
35. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
Watanabe M; Iwahashi K; Kugoh T; Suwaki H
Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299
[TBL] [Abstract][Full Text] [Related]
36. Mephenytoin phenotyping: lack of haematologic effect and timing of urine collections.
Relling MV; Ayers D; Heideman RL
Pharmacogenetics; 1991 Oct; 1(1):42-9. PubMed ID: 1844822
[TBL] [Abstract][Full Text] [Related]
37. CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.
Crespi CL; Chang TK; Waxman DJ
Methods Mol Biol; 1998; 107():135-9. PubMed ID: 14577222
[No Abstract] [Full Text] [Related]
38. Biochemistry and molecular biology of the human CYP2C subfamily.
Goldstein JA; de Morais SM
Pharmacogenetics; 1994 Dec; 4(6):285-99. PubMed ID: 7704034
[TBL] [Abstract][Full Text] [Related]
39. Human liver mephenytoin 4'-hydroxylase cytochrome P-450 proteins and genes.
Brian WR; Ged C; Bellew TM; Srivastava PK; Bork RW; Umbenhauer DR; Lloyd RS; Guengerich FP
Drug Metab Rev; 1989; 20(2-4):449-65. PubMed ID: 2680390
[No Abstract] [Full Text] [Related]
40. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
